Ignite Creation Date:
2024-05-06 @ 7:06 AM
Last Modification Date:
2024-10-26 @ 11:44 AM
Study NCT ID:
NCT02462538
Status:
TERMINATED
Last Update Posted:
2022-03-03
First Post:
2015-05-18
Brief Title:
Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK ALCL
Sponsor:
Arbeitsgemeinschaft medikamentoese Tumortherapie
Organization:
Arbeitsgemeinschaft medikamentoese Tumortherapie
Organization Data
Organization:
Arbeitsgemeinschaft medikamentoese Tumortherapie
Class:
OTHER
Study ID:
AGMT_ALCL1
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Arbeitsgemeinschaft medikamentoese Tumortherapie
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None